Pathogenesis and treatment of xanthomatosis - Blood Journal

Pathogenesis and treatment of xanthomatosis - Blood Journal

From www.bloodjournal.org by guest on March 14, 2018. For personal use only. Review article Pathogenesis and treatment of xanthomatosis associated w...

241KB Sizes 0 Downloads 4 Views

Recommend Documents

and the Pathogenesis of Hemoglobin Instability - Blood Journal
Medical. Center. Washington,. D. C. . and the. Department of Cell and. Molecular ...... Lehmann. H: Unstable haemoglobin

Asthma: pathogenesis and novel drugs for treatment
for treatment. J Tod Olin , Michael E Wechsler. Introduction ...... Burch J, Griffin S, McKenna C, Walker S, Paton J, Wr

Systemic review: the pathogenesis and pharmacological treatment of
A thorough list of prescribed and ... hensive list of all agents with putative efficacy in hiccups ... time, but frequen

TREATMENT OF LEG ULCERS IN SICKLE CELL - Blood Journal
Shaare Zedek Medical Center. Jerusalem, Israel. REFERENCES. 1. Koshy M, Entsuah R, Koranda A, Kraus AP, Johnson R,. Bell

Treatment of Acute Graft-Versus-Host Disease With - Blood Journal
By Claudio Anasetti, John A. Hansen, Thomas A. Waldmann, Frederick R. Appelbaum, Jennifer ...... Strom TB, Kelley VR, Mu

Blood Forum - Blood Journal
May 30, 2013 - (Blood. 2013;121(22):4439-4442). The doctrine of justum pretium, or just price ..... As physicians, we fo

Simplified Determination of Blood Adenosine - Blood Journal
Firefly. System. By ERNEST. BEU-rLER. AND. MARYELLEN. C. BALUDA. DENOSINE. TRIPHOSPHATE. (ATP) appears to play a critica

Normal and Variant Isoenzymes of Human Blood Cell - Blood Journal
the Isoenzyme. Patterns in. Hemolytic. Anemia. By. CIGDEM. ALTAY,. CHESTER. A. ALPER. AND. DAvm. G. NATHAN. Electrophore

Untitled - Blood Journal
Jul 7, 2008 - Hackney, J.A., P. Charbord, B.P. Brunk, C.J. Stoeckert, I.R. Lemischka, and K.A. ... an endoplasmic reticu

Regular Article - Blood Journal
Apr 2, 2015 - Claudia Guida,1,2 Sandro Altamura,1,3 Felix A. Klein,2 Bruno Galy,2 Michael Boutros,4 Artur J. ...... Laft

From www.bloodjournal.org by guest on March 14, 2018. For personal use only.

Review article

Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy *Raphael Szalat,1,2 *Bertrand Arnulf,1,2 Lionel Karlin,1 Michel Rybojad,3 Bouchra Asli,1 Marion Malphettes,1 Lionel Galicier,1 Marie-Dominique Vignon-Pennamen,4 Ste´phanie Harel,1 Florence Cordoliani,3 Jean Gabriel Fuzibet,5 Eric Oksenhendler,1 Jean-Pierre Clauvel,1 Jean-Claude Brouet,1,2 and Jean-Paul Fermand1,2 1De ´ partement d’immunologie clinique, Hoˆpital Saint Louis, Paris, France; 2EA3963, Institut Universitaire d’He´matologie, Paris, France; 3Service de dermatologie and 4Service d’anatomie pathologique, Hoˆpital Saint Louis, Paris, France; and 5Service de me´decine interne, Hoˆpital de l’Archet, Nice, France

Xanthomas are a common manifestation of lipid metabolism disorders. They include hyperlipemic xanthoma, normolipemic xanthoma, and a related condition, necrobiotic xanthogranuloma (NXG). All 3 forms can be associated with monoclonal immunoglobulin (MIg). In an attempt to improve diagnosis, understanding, and treatment of this association, we retrospectively analyzed a personal series of 24 patients (2 hyperlipemic xanthoma, 11 normolipemic xanthoma, and 11 NXG) and 230 well-documented reports from

the literature. With the exception of the nodules and plaques featured in NXG, the clinical presentation of xanthomatous lesions usually resembled that seen in common hyperlipidemic forms and could not be used to suspect MIg-associated xanthomas. Extracutaneous sites were not rare. The MIg was an IgG in 80% of cases. Myeloma was diagnosed in 35%. Hypocomplementemia with low C4 fraction was present in 80% of studied patients. Low C1 inhibitor serum levels were found in 53%. Cryoglobulinemia was detected in

27%. These abnormalities suggest immune complex formation because of interactions between the MIg and lipoproteins and argue in favor of a causal link between MIg and xanthomas. Monoclonal gammopathy therapy could thus be an option. Indeed, among the patients who received chemotherapy, hematologic remission was accompanied by improvement in xanthoma lesions in several cases. (Blood. 2011;118(14):3777-3784)

Introduction Xanthomas are a common manifestation of lipid metabolism disorders that are characterized by the deposition of yellowish cholesterol-rich material in large foam cells accumulating in the skin and the tendons. Xanthomatosis is usually associated with hyperlipidemias, both primary and secondary types, and morbidity and mortality of this condition are related to atherosclerosis and pancreatitis. Xanthomas can also occur in normolipemic patients, although rarely, with the exception of lipid deposits limited to the palpebral area, the so-called xanthelasma.1 Xanthoma lesions have been described with or without hyperlipidemia in association with monoclonal immunoglobulin (MIg). Cremer et al2 first reported on this association in 1937. Since then, 3 distinct forms have been identified: hyperlipemic xanthoma (HX), diffuse plane normolipemic xanthoma (NX), and the socalled necrobiotic xanthogranuloma (NXG). Xanthoma lesions in HX and NX are similar (yellow maculae or papules, although NX lesions are usually diffuse and plane), whereas HX lesions are more polymorphic and can include tuberous, tendinous, palmar, or eruptive xanthoma.3 In contrast, NXG lesions are firm papules, nodules, or plaques, the color of which varies from violaceous to red-orange or yellow.4 HX and NX are characterized by foam cell infiltration in the skin, whereas NXG is featured by the association of necrobiosis, giant cells (Touton type), asteroid bodies, cholesterol clefts, and foam cells.5 It could be argued that the association of xanthomatosis with monoclonal gammopathy is fortuitous, particularly in the elderly

because of the relatively high prevalence of monoclonal gammopathy in this population. However, the antilipoprotein activity of MIg has been documented in some patients with HX and NX, and this points toward a cause-and-effect link between the 2 disorders.3,6,7 The physiopathology of NXG remains much less well understood than the 2 other forms.8 Therapeutic options for patients with xanthoma lesions and associated MIg, which depend on the demonstration of a relationship between the 2 disorders, are currently poorly defined. With a view to gaining further knowledge of the association of xanthoma and MIg, we analyzed a personal series of 24 patients with respect to clinical, biologic, pathologic, and therapeutic parameters and compared our findings with existing data from the literature.

Submitted May 26, 2011; accepted June 24, 2011. Prepublished online as Blood First Edition paper, July 14, 2011; DOI 10.1182/blood-2011-05-356907.

© 2011 by The American Society of Hematology

Methods Ten French medical units of dermatology, internal medicine, or hematology were questioned about any patients with HX, NX, or NXG followed between 1980 and 2010. Inclusion criteria were: (1) the presence of an MIg as detected by serum or urine electrophoresis and/or immunoelectrophoresis; (2) xanthomatous cutaneous lesions confirmed by a biopsy showing foam cell infiltration or necrobiosis, cholesterol clefts, and Touton giant cells for xanthoma and NXG, respectively; and (3) available tests for plasma cholesterol and triglycerides. Diagnosis of associated monoclonal gammopathy was established according to the International Myeloma Working Group. A histopathologic examination was usually required to confirm potential extracutaneous lesions. When this was possible, biopsies

*R.S. and B.A. contributed equally to this study.

BLOOD, 6 OCTOBER 2011 䡠 VOLUME 118, NUMBER 14

3777

From www.bloodjournal.org by guest on March 14, 2018. For personal use only. 3778

BLOOD, 6 OCTOBER 2011 䡠 VOLUME 118, NUMBER 14

SZALAT et al

Table 1. Characteristics and treatment of patients included in the present series Patient no.

Diagnosis

Age, y

Sex

MIg

Gammopathy

Atherosclerosis

Treatment

1

NXG

67

Female

IgG1␬

Stage I MM

No*

Thalidomide (no improvement)

2

NXG

65

Female

IgG␬

Stage I MM

No

Steroids/immunosuppressive therapy

3

NXG

63

Male

IgG␭

MGUS/

Yes, ischemic

Thalidomide/bortezomib (improvement), PR

4

NXG

71

Female

IgG␭

MGUS

Yes, aortic aneurysm

Steroids/chlorambucil† (improvement), PR

5

NXG

72

Female

IgG␬

MGUS

Yes, hypertensive

Steroids/chlorambucil† (improvement), PR

(no improvement) myelodysplasia

cardiopathy

cardiopathy 6

NXG

48

Male

IgG1␬

Lymphoma

No

Chlorambucil/rituximab/fludarabine/

7

NXG

53

Male

IgG1␬

MGUS

No

Chlorambucil†/rituximab†/fludarabine†/

cyclophosphamide (improvement), VGPR cyclophosphamide/thalidomide/ dexamethasone (improvement), VGPR 8

NXG

65

Female

IgG␬

Overt MM

No

Melphalan/prednisone/interferon-␣

9

NXG

78

Female

IgG␬ IgM␭

MGUS

No

None

(improvement), VGPR 10

NXG

65

Female

IgG␭

Overt MM

No

None

11

NXG

68

Female

IgG␬

MGUS

No

None

12

NX

72

Female

IgG␬

MGUS

No

None

13

NX

37

Female

IgG␬

Stage I MM

No*

High-dose therapy and autotransplant

14

NX

75

Male

IgG1␭

Overt MM

No*

Melphalan/prednisone (no improvement)

15

NX

60

Male

IgG␬ IgM␬

Waldenström/

No

Chlorambucil

Yes, ischemic

None

(no

improvement)

amyloidosis 16

NX

68

Male

IgG1␬

MGUS

cardiopathy, severe arteritis 17

NX

66

Male

IgG␭

MGUS

No*

None

18

NX

52

Male

IgG␭

MGUS

No*

None

19

NX

46

Male

IgG␭

MGUS

No

None

20

NX

42

Male

IgG␭

MGUS

No

None

21

NX

63

Male

IgG␭

MGUS

No

None

22

NX

45

Male

IgG␬

MGUS

No

None

23

HX

74

Female

IgG1␬

Overt MM

Yes, ischemic

Bortezomib/thalidomide/dexamethasone

cardiopathy

(complete hematologic and cutaneous response)

24

HX

55

Male

IgG1␬

Overt MM

Yes, ischemic cardiopathy

Thalidomide/high-dose therapy and autotransplant (improvement), VGPR

IgG1␬ PR indicates partial response; and VGPR, very good partial response. *Arterial Doppler evaluation. †Chlorambucil, rituximab, and even fludarabine in patients 4, 5, and 7 were used more for their immunosuppressive properties rather than as antiproliferative drugs.

of patient’s skin lesions were stained by the CD163 antibody (Novocastra Laboratories) and studied by immunohistochemistry. Diagnosis of atherosclerosis was considered if the patient had a cardiovascular event in their background or during the follow-up and taking into account arterial Doppler evaluation when available. In parallel, a PubMed/Medline review of the literature was performed using the following key words: “xanthoma paraprotein,” “diffuse plane normolipemic xanthoma,” “hyperlipidemia myeloma,” and “necrobiotic xanthogranuloma.”

Results Personal series

Data from 24 patients, of whom 17 were still alive and 7 were lost to follow-up or had died, were retrospectively studied. There were 13 men and 11 women (sex ratio ⫽ 1.2). Mean age at diagnosis was 61.25 ⫾ 11.4 years (range, 37-78 years). In 87.5% (21 of 24) of cases, the skin lesions led to the discovery of the MIg. The periorbital area was involved in 83.5% (20 of 24) of cases (Tables 1-3). The skin lesions of cases of NXG were always nodules or

plaques (Figure 1), whereas those of HX or NX were maculae or papules. One patient with NX had a diffuse xanthodermia (Figure 1). Three patients had both NX and NXG (confirmed by pathology). Atherosclerosis was found in 5 patients (21%). Extracutaneous lesions were found in 33% (8 of 24) of cases, mostly in patients with NXG (54.5%). In 4 patients, this consisted of a symptomatic orbital mass. In the remaining 4 patients, infiltration by foam cells was discovered on a systematic bone marrow examination (n ⫽ 3), on the biopsy of an enlarged inguinal lymph node (n ⫽ 1), and on a hepatic biopsy performed because of abnormalities in liver enzymes (n ⫽ 1). The MIg was an IgG in all 24 cases (100%), ␬ in 15 (62.5%), and ␭ in 9 (37.5%). Three patients had a biclonal gammopathy (2 had an IgG and an IgM and 1 had 2 IgG). The IgG subclass was IgG1 in the 8 cases studied. Underlying monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) were diagnosed in 14 (58%) and 8 (33%) cases, respectively. In addition, Waldenstro¨m disease with amyloidosis and B-cell non-Hodgkin lymphoma of lymphoplasmocytic type were diagnosed in 1 case each. Three patients (patients 3, 7, and

From www.bloodjournal.org by guest on March 14, 2018. For personal use only. BLOOD, 6 OCTOBER 2011 䡠 VOLUME 118, NUMBER 14

XANTHOMATOSIS AND MONOCLONAL GAMMOPATHY

3779

Table 2. Characteristics of complement, C1 inhibitor levels, and cryoglobulinemia Patient no.

CH50

C3

C4

Cryoglobulin

C1inh

1

0%

Low

⬍ 15%

Negative

⬍ 30%

2

66%

Normal (0.87 mg/L)

⬍ 25%

Negative

NA

3

75%

Normal (1.3 mg/L)

⬍ 25%

Negative

Normal

4

Low*

Normal

40%

NA

NA

5

Low*

Low*

Low*

Negative

NA

6

Very low*

Normal

Very low*

NA

NA

7

NA

Normal

⬍ 25%

NA

NA

8

NA

Lower limit of normal (0.63 mg/L)

⬍ 40%

Negative

NA

9

NA

NA

NA

NA

NA

10

⬍ 10%

⬍ 50%

⬍ 5%

NA

Low (0.19 g/L)

11

Normal

Normal

⬍ 25%

NA

Normal

12

Low*

Normal

Very low*

NA

NA Normal

13

25%

Normal (1.04 mg/L)

⬍ 25%

Positive (type 1)

14

⬍ 25%

75%

⬍ 25%

Negative

⬍ 30%

15

Normal (83%)

Normal (0.9 mg/L)

Normal

Positive (type 3)

NA

16

Normal

Normal

Low

Negative

NA

17

Low*

Normal (1.02 mg/L)

⬍ 10%

Negative

Normal

18

Normal

Normal

⬍ 10%

NA

Normal

19

⬍ 25%

Normal

⬍ 10%

Negative

Normal NA

20

15%

Normal

⬍ 25%

Negative

21

NA

NA

NA

NA

NA

22

⬍ 25%

83%

⬍ 25%

Negative

0%

23†

⬍ 25%

Normal

⬍ 25%

Negative

NA

24

⬍ 25%

45%

⬍ 25%

Negative

NA

NA indicates not applicable; very low, ⬍ 25% of the normal range; and deficiency, ⬍ 30% of the normal range. *Corresponding value not available. †Normalization of complement levels while chemotherapy induced complete remission. (Only 1 case with available complement values on chemotherapy.)

14; 17%) developed myelodysplasia: 2 after being treated by chemotherapy and 1 at diagnosis. The complement study (Table 2) revealed a decrease in 50% haemolytic complement (CH50) activity in 83% (16 of 20) of studied patients, with a low C4 fraction in 95.5% (21 of 22). The serum C4 level was markedly low (⬍ 25% of normal value) in 81% (17 of 21) of the patients. Unexpectedly, a decrease in the C1 inhibitor level was found in 40% (4 of 10) of cases. A small amount of cryoglobulin was detected in 2 of 15 patients (13%), of type I and III in 1 case each. High levels of triglycerides as well as total cholesterol character-

ized dyslipidemia in HX. In all NXG cases, plasma lipid levels were normal or low. In all patients, histologic findings were in accordance with the selection criteria. In 10 skin biopsy samples, an immunohistochemical study using CD163 staining as a monocyte/macrophage marker was performed. Foam cells as well as Touton giant cells were consistently CD163⫹ in all cases of HX, NX, and NXG (Figure 2). Eleven patients were treated by standard-dose conventional chemotherapy, and 2 patients received a high-dose regimen (melphalan 200 mg/m2) supported by autologous blood stem cell

Table 3. Literature data HX Literature

NX Present series

Literature

NXG Present series

Literature

Present series

Total

No. of cases

37

2

63

11

130

11

254

Mean age, y (range)

53.9 (31-80)

64.5 (55-74)

62.05 (37-83)

56.9 (37-75)

56.23 (17-88)

65 (48-78)

59.76

Sex ratio (female/male) 1.2 (19/17)

1 (1/1)

1 (31/32)

0.2 (2/9)

1.5 (78/52)

2.7 (8/3)

1.2 (139/114)

Palpebral lesions

2/2

32/63

10/11

94/130

8/11

155/254 (61%)

Extracutaneous lesions 8/37

1

8/63

1/11

23/130

6/11

47/254 (18.5%)

Cryoglobulinemia

5/8

0/2

5/31

2/8

10/26

0/5

22/80 (27.5%)

MIg isotype

14 IgG

2 IgG

56 IgG (89%) 1 IgM␬, 11 IgG

105 IgG (81%), 4 IgA,

11 IgG

200 IgG (79%)

9/37

1 IgM ␭ 1 IgA, 1 BJ

2 IgM, 8 UK

␬, 4 UK Associated gammopathy

31 MM 4 MGUS 1 CLL 2 MM 1 Waldenström

30 MM, 26 MGUS, 2 MMCL,

2 MM, 8 MGUS, 1 Waldenström

20 MM, 68 MGUS, 2 CLL, 4 MM, 6 MGUS, 90 MM 3 NHL, 1 HL, 22 UK

1 NHL

1 CLL, 1 NHL, 2

(35.4%), 111 MGUS (44%)

amyloidosis Low serum C4 fraction

1/2

2/2

26/31

9/10

23/33

10/10

71/88 (81%)

⬍ 25% of normal

0/1

2/2

15/26

8/9

6/14*

7/10

38/62 (61%)

0/1

NA

12/21

2/6

4/6

2/4

20/38 (53%)

values Low C1 inhibitor level

CLL indicates chronic lymphoid leukemia; BJ, Bence Jones proteinuria; UK, unknown; MMCL, myelomonocytic chronic leukemia; NHL, non-Hodgkin lymphoma; and HL, Hodgkin lymphoma. *Corresponding to available values.

From www.bloodjournal.org by guest on March 14, 2018. For personal use only. 3780

SZALAT et al

BLOOD, 6 OCTOBER 2011 䡠 VOLUME 118, NUMBER 14

melphalan and an autotransplant. In the 2 HX cases, chemotherapy led to normalization of blood lipid levels. Comparison with existing literature

Figure 1. Aspects of xanthoma of our patients. (A-B) NXG in patient 1. (C) NX in patient 12. (D) Diffuse xanthodermia featuring NX in patient 11. (E-F) HX in patient 23 before (E) and after (F) chemotherapy.

transplantation (Table 1). Skin lesions improved after treatment in 8 patients who presented with HX or NXG, whatever the drug (chlorambucil, melphalan, thalidomide, or bortezomib). In these cases, regression of skin lesions was associated with a reduction in the MIg serum level. Of note, the 3 patients (patients 6, 7, and 22) who achieved an apparent complete hematologic response also experienced a complete dermatologic response. When the relapse occurred, it was associated with the reappearance of the skin xanthomatous lesions in these 3 cases. Importantly, in an additional patient (case 23) who achieved a sustained hematologic and dermatologic complete response (Figure 1), complement serum levels also return to normal values. In the 3 patients with NX, treatment was unsuccessful on skin lesions, and no decrease in MIg level was observed, even in patient 11 who received high-dose

Figure 2. Skin biopsies of patients with NXG and NX. Touton giant cells (hematoxylin coloration; A) with positive staining for CD163 in immunohistochemistry in NXG (B). (C) Dermal infiltration by spumous cells. (D) Positive staining for CD163 in NX. Images were acquired with an Olympus Bx51 microscope (A, 20⫻/0.5; B, 20⫻/0.5; C, 5⫻/0.16; and D, 5⫻/0.16) in Axiocam MRc (Zeiss; Axiovision 4.8.2).

We reviewed 216 well-described cases of xanthomatosis associated with MIg in the literature, including 37 cases of HX,3 63 of NX,6,9-30 and 116 of NXG4,8,31-47 (Tables 3 and 4). The main patient characteristics are listed in Tables 3 and 4. The 37 cases of HX included 17 men and 19 women (sex ratio ⫽ 0.9) with a mean age of 53.9 ⫾ 10.75 years (range, 31-80 years). All types of xanthomas were described (plane, eruptive, diffuse, papular). Periorbital involvement was present in 24.3% (9 of 37) of the patients. Extracutaneous lesions were reported in 8 cases (21%), including bone (n ⫽ 148), lung (n ⫽ 149), hepatic (n ⫽ 150), palatine (n ⫽ 151), and tendinous (n ⫽ 452-55) localizations. Two patients had splenomegaly and 1 patient had hepatomegaly, without mention of the cause. Cardiovascular disease or atherosclerosis was present in 14 cases (37%). Skin lesions preceded the discovery of the MIg in 92% (34 of 37) of the cases. The MIg was IgG, IgA, and IgM in 38% (n ⫽ 14), 35% (n ⫽ 13), and 2.5% (n ⫽ 1) of patients, respectively. MIg isotype was not reported for 9 patients. The underlying hemopathy was MM in 31 (84%), MGUS in 4 (11%), and chronic lymphocyte leukemia and Waldenstro¨m disease in 1 case each. Serum complement levels were assessed in only 2 patients, and a low C4 value was reported in 1.56 Cryoglobulinemia was found in 5 of the 8 patients studied, without characterization in any of the cases. Type 3 dyslipidemia was the most frequent (63%, 24 of 38), but all types were reported. Histopathologic analysis revealed foam cells in all of the cases with no IgG on immunofluorescence in 2. Touton cells were found in 2 patients. Of the 15 treated patients,3 treatment was reported as effective in 53% (8 of 15) of the patients who received standarddose chemotherapy using alkylating agents and steroids (n ⫽ 6) or adriamycin and steroids (n ⫽ 1). In addition, 1 patient was treated by high-dose therapy and autotransplant, which produced both hematologic and cutaneous complete remission; at myeloma (and hyperlipemia) relapse, he received an allogeneic transplant, but there is no information about subsequent progression of the xanthomatous lesions.3

From www.bloodjournal.org by guest on March 14, 2018. For personal use only. BLOOD, 6 OCTOBER 2011 䡠 VOLUME 118, NUMBER 14

XANTHOMATOSIS AND MONOCLONAL GAMMOPATHY

3781

Table 4. Xanthoma topography HX Topography

Literature (n ⴝ 38)

NX

Present series (n ⴝ 2)

Literature (n ⴝ 63)

NXG Present series (n ⴝ 11)

Literature (n ⴝ 130)

Present series (n ⴝ 9)

Total (N ⴝ 253)

Periorbital/xanthelasma

9 (24%)

2 (100%)

32 (51%)

10/11 (91%)

94/130 (72%)

8/11 (78%)

155 (61%)

Trunk

11 (29%)

1/2

28 (44%)

6/9

70/130 (53%)

6/11

122 (48%)

Folds/hand

17 (45%)

1/2

26 (41%)

7/11

4 (3%)

2/11

Members (arms/legs)

25 (66%)

2/2

27(43%)

10/11

47/81 (58%)

6/11

Face

4 (10.5%)

0/2

7 (11%)

5/11

21/113 (18.5%)

5/11

Diffuse xanthoderma

1 (2%)

0/2

8 (13%)

1/11

0

0/11

Extracutaneous

1 bone

1/2

1 conjunctivitis

1/11

7 lung

6/11

1 hepatic

Medullar

1 episcleritis

lymph

6 cardiac

4 orbitary mass

1 lung

5 oral cavity

node

2 hepatic

2 medullar

1 palatine

1 digestive

2 spleen

1 hepatic

4 tendinous

1 muscle

4 oral cavity

1 aortic valve

3 orbit

1 tendinous

1 penis, 1 kidney, 1 mastoid,

57 (22.5%) 117 (46%) 48 (19%) 10/254 (4%) 53 (21%)

1 medulla, 1 facial nerve

The 63 reviewed cases of NX included 32 men and 31 women (sex ratio ⫽ 1) with a mean age of 62.05 ⫾ 8.76 years (range, 37-83 years). Most often, xanthomas were featured by diffuse plane eruptions, but also by maculae, papules, or nodular lesions. Periorbital involvement was present in 51% (32 of 63). Extracutaneous lesions were noted in 12.7% (n ⫽ 8), including 2 patients who had several localizations. The most frequent was in the oral cavity (n ⫽ 5).16,57-59 Others included ophthalmic (n ⫽ 2),57,60 digestive (n ⫽ 1),61 tendinous (n ⫽ 1), and muscular (n ⫽ 1)16 localizations. In 1 patient, the aortic valve had been replaced because of severe aortic insufficiency, and its histology revealed the presence of foam and Touton cells.57 Atherosclerosis was reported in only 1 patient.62 In 95% (60 of 63) of the cases, the skin lesions led the clinician to investigate for MIg. The MIg was an IgG in 89% (56 of 63), ␬ in 55% (28 of 51), and ␭ in 45% (23 of 51). In the 10 studied cases, the IgG belonged to the IgG1 subclass. The underlying hematologic condition was MM in 48% (n ⫽ 30), MGUS in 41% (n ⫽ 26), myelomonocytic leukemia (n ⫽ 2), non-Hodgkin lymphoma (n ⫽ 1), and chronic lymphocyte leukemia (n ⫽ 1). In 2 cases, amyloid deposits, presumed to be AL, were detected. Hypocomplementemia was found in 84% (26 of 31) of studied cases. C4 serum values were low in all cases, and the C4 serum level was below 25% of the lower limit of the normal value in 15 patients. C1 inhibitor level was low in 57% (12 of 21). Cryoglobulinemia was detected in 16% of the patients (5 of 31). Pathologic analysis revealed foam cells without any Ig deposits on immunofluorescence in the 11 studied cases. Touton cells were found in 10 cases (16%). Seven patients were treated by various standard chemotherapy regimens. Three achieved a partial hematologic remission, which was accompanied by some improvement in xanthomatous lesions.18,28,63 Of note, 1 patient received the hypolipemic agent probucol, which was reported to be effective on skin lesions.21 The 130 reviewed cases of NXG included 116 cases associated with an MIg (89%). There were 52 men and 78 women (sex ratio ⫽ 0.67) with a mean age of 56.2 ⫾ 14.2 years (range, 17-88 years). Skin lesions were red-brown nodules or plaques, sometimes with ulcerations or telangiectasia. Periorbital involvement was present in 72%. In 90% of the cases, more than 1 site was involved. In 5 patients, xanthoma and NXG were present at the same time.46,64-67 Extracutaneous lesions were reported in 23 cases (17.6%), including 6 patients with several localizations. They were pulmonary (n ⫽ 7),8 cardiac (n ⫽ 6),8,37 oral cavity (n ⫽ 4),38,65 orbital (n ⫽ 3),8 hepatic (n ⫽ 2),8,37 spleen (n ⫽ 2),8 medullar (n ⫽ 1),68 genital (penis; n ⫽ 1),34 mastoid (n ⫽ 1),32 facial nerve

(n ⫽ 1),32 and renal (n ⫽ 1).69 In addition, splenomegaly was noted in 22 patients (17%) and hepatomegaly in 17 (13%), without any further information. Ophthalmic manifestations, mainly scleritis, chorioiditis, or conjunctivitis, were reported in 29 cases.70 Atherosclerosis was present in 14 (11%). The discovery of the MIg preceded the skin lesions in only 2 cases.45,71 The MIg was an IgG in 105 patients (82%), an IgA in 4, and an IgM in 2. MIg isotype was not reported in 8 patients. The light chain isotype was ␬ for 71% and ␭ for 28% of cases. Three patients had a biclonal gammopathy. Hematologic diseases were MGUS in 59% (n ⫽ 68) and MM in 17% (n ⫽ 20) of cases. Two cases of chronic lymphocyte leukemia and 4 cases of B-cell lymphoma were also reported. One case was also associated with amyloidosis.72 Serum C4 level was low in 70% (23 of 33) of studied cases, including in 6 patients in whom it was below 25% of normal value. C1 inhibitor level was decreased in 4 of 6 observations. A serum cryoglobulin was detected in 38.5% (10 of 26) of studied cases; it was never characterized. Abnormal lipid results were reported in 16% (n ⫽ 21) of patients. Peripheral leukopenia was present in 43 patients (33%). Pathology study revealed foam cells, necrobiosis (except in 1), and Touton cells in all cases sometimes with cholesterol clefts or asteroid bodies. Immunohistochemistry for CD1a and PS100 (when tested) was always negative. Treatment, which was reported in 71 cases, was successful in 55 (77%) patients who received melphalan and steroids (n ⫽ 17), Chlorambucil (n ⫽ 16), high-dose therapy and auto-transplant (n ⫽ 1), systemic steroids (n ⫽ 6), thalidomide (n ⫽ 3),32,73,74 lenalidomide (n ⫽ 1),47 plasmapheresis and hydroxychloroquine (n ⫽ 1), cyclophosphamide and steroids (n ⫽ 2), azathioprine (n ⫽ 2), infliximab (n ⫽ 1), and local therapy, including local steroids injection, surgery, or laser CO2 (n ⫽ 5). Of note, the xanthomatous lesions of the 4 patients who received an immunomodulatory drug, usually in combination with dexamethasone, were considered to be improved in all cases. Variations in the MIg level were rarely reported and inconsistent: some reported a decrease in levels accompanied by an improvement in cutaneous lesions,34,75 whereas others reported that skin lesions persisted despite a reduction in MIg levels.76

Discussion We retrospectively analyzed data from 240 patients presenting with xanthomatosis associated with MIg, including a personal series of 24 patients and 216 case reports that were published in the

From www.bloodjournal.org by guest on March 14, 2018. For personal use only. 3782

SZALAT et al

literature. In nearly all cases (97%), the MIg was discovered subsequent to the skin lesions. Prevalence is slightly higher in women than men, and onset is usually in the sixth decade of life (mean age, 59.76 years). Xanthomas were localized in the periorbital area in 61% of the cases and on the extremities or members in half. Clinical presentation of xanthomas resembles that seen in general hyperlipidemic forms and is usually not suggestive of the presence of an associated MIg, except for the nodules and plaques, sometimes with an inflammatory aspect, that are characteristic features of the so-called NXG: MIg is found in ⬃ 80% of patients with this presentation.8 Although we lack sufficient data to precisely assess the frequency of xanthomatosis and MIg association, it would seem reasonable to recommend performing at least a serum electrophoresis when faced with a xanthoma lesion, with the exception of isolated xanthelasma, particularly in the absence of abnormalities of serum lipid tests. Indeed, although NX is usually much less frequent than HX, it was reported more often in association with MIg, both in our series and in the literature. When MIg is present in the setting of xanthoma, it is an IgG in 83% (200 of 240) of cases, and the underlying hematologic condition is either MGUS or overt lymphoid malignancies, such as myeloma, approximately half of each. In our experience, a good way of testing whether the association between xanthomatosis and MIg is fortuitous in view of the high prevalence of monoclonal gammopathy in the general population is to check the serum complement level. Overt complement abnormalities are highly uncommon in patients with xanthoma alone and in patients with a noncryoprecipitating MIg,77 whereas a low serum C4 level was present in all of our patients except 1. Data from the literature confirmed that low serum C4 is frequent in such patients as it was detected in ⬃ 75% (50 of 66) of studied cases. In our series, we found that CH50 activity was usually decreased, whereas the serum level of the C3 fraction of the complement was variable. A decrease in the level of C1 inhibitor was also frequently observed, both in our series and in the literature. Patients with low C1 inhibitor had no symptoms of angioneurotic edema; and in the 2 studied cases, no C1 inhibitor antibodies were detected. Of note, a high rate of cryoglobulinemia was found (27.5% of all patients), which may explain complement abnormalities at least in some patients. However, decreases in C4 and C1 inhibitor levels were also observed in the absence of detectable serum cryoglobulin. In any case, the complement abnormalities are consistent with an activation of the classic complement pathway, which probably indicates immune complex formation that may be the result of antigen-antibody interactions between the MIg and various lipoproteins (see later in “Discussion”). Accordingly, this argues in favor of a causal link between the monoclonal gammopathy and the xanthoma lesions. This is reinforced by the normalization of complement values that we observed in 1 patient who achieved a hematologic (and dermatologic) complete response. Whether or not those patients without detectable complement abnormalities reflect a fortuitous association remains an open question. We observed complement abnormalities in all 3 types of xanthoma associated with MIg: HX, NX, and NXG. Additional data suggest that these 3 conditions may be part of a common syndrome. First, HX and NX lesions can coexist with lesions of NXG in the same patient as seen both in patients from our series and from the literature.46,64-67 Second, the 3 forms share common histologic features, namely, the presence of foam cells and Touton cells. The latter is typically considered as characteristic of NXG; and, indeed, we did not find such cells in any of our patients with

BLOOD, 6 OCTOBER 2011 䡠 VOLUME 118, NUMBER 14

HX and NX. However, Touton cells have been observed in HX and NX in several cases in the literature.20,49,57,62,78-85 Moreover, as demonstrated here, foam cells and Touton cells share phenotypic characteristics, including the surface expression of the CD163 antigen, which would suggest a common macrophagic origin. Finally, immune complex formation resulting from antibody activity of the MIg directed against various lipoproteins appears to represent a common physiopathologic pathway leading to a lipid accumulation in the macrophagic cells. In HX and NX, an interaction between the MIg and lipoprotein has been more or less well documented in 16 and 9 cases, respectively.3,21 In HX, this interaction may alter the lipoprotein linkage to its receptor leading to hyperlipidemia,55 whereas in NX the interaction seems to result in enhanced lipid accumulation in the macrophages.6 Few data are available for NXG, but an interaction between the MIg and a lipoprotein and activation of circulating monocytes has been described in 1 case each.8,9 Assuming a common physiopathology of the 3 forms of xanthoma with MIg, the different clinical presentation might be explained by a different target of the MIg or by host-dependent variable responses to the lipoprotein deposits in monocytes and macrophages. Importantly, the incidence of atherosclerosis appears to be low in NX and NXG, whereas it is high in HX. Accordingly, an arterial evaluation should be systematically performed only in those patients with hyperlipemia. Extension of xanthomatous lesions, particularly outside the skin territory, appears to be more frequent in NXG in which extracutaneous lesions were found in 20.5% of evaluable cases. In any case, searching for such deposits by computed tomography scan or other imaging techniques should be recommended in patients with suggestive symptoms. If we consider then that there is a causal link between the MIg and the xanthoma lesions, monoclonal gammopathy therapeutic options should be discussed. Indeed, hematologic remission may produce an improvement of xanthoma lesions, as illustrated by several cases both from our series and from the literature. Moreover, in some of these cases, myeloma relapse was simultaneously featured by xanthoma relapse. The deleterious effect of MIg may be modulated by intravenous immunoglobulins, although these have been used in only very few patients, with striking efficacy in 2 patients with NXG.86 However, most available therapeutic options aim to reduce MIg production using chemotherapeutic drugs, alkylating agents, other classic drugs, or the so-called new antimyeloma agents, including bortezomib, thalidomide, and lenalidomide. These drugs, either incorporated in standard-dose regimen or in high-dose protocol with autologous transplantation, are obviously indicated in patients with xanthoma and overt MM. In contrast, in patients with stage I MM or even more with MGUS, they should be proposed only in patients in whom the cause-andeffect link between the 2 disorders is documented (ie, in patients with hypocomplementemia). In addition, MGUS patients who are candidates for chemotherapy should present with disabling or “painful” lesions, extracutaneous localization, and/or symptomatic atherosclerosis. Patients with NX are usually asymptomatic; and, as documented here, currently available chemotherapeutic options appear to be poorly effective in this setting. Accordingly, in the absence of progression of the underlying monoclonal gammopathy, chemotherapy should be proposed only in some patients with NXG and HX. Although thalidomide or lenalidomide in combination with dexamethasone may represent a good option, current data are not sufficient to draw any definitive conclusions. Xanthomas should lead clinicians to search for the presence of an MIg, especially in patients with NXG or normal blood lipid

From www.bloodjournal.org by guest on March 14, 2018. For personal use only. BLOOD, 6 OCTOBER 2011 䡠 VOLUME 118, NUMBER 14

XANTHOMATOSIS AND MONOCLONAL GAMMOPATHY

levels. A good way of testing whether or not the association is fortuitous is to check serum complement levels. If there is no progression of the underlying monoclonal gammopathy, some patients with hypocomplementemia, mainly those with NXG and HX and with disabling lesions, extracutaneous localization, and/or symptomatic atherosclerosis, could benefit from chemotherapy.

Acknowledgments The authors thank Pr Cathe´bras, Pr Cribier, Pr Dhote, Pr Jaccard, Dr Lambotte, Dr Sene, Philipe Lesnik, and Wilfried Le Goff (Inserm UMR-S U939) for their contribution to this work.

3783

Authorship Contribution: R.S., B.A., and J.-P.F. designed and performed the research, analyzed data and wrote the paper; L.K., M.R., B.A., M.M., L.G., S.H., F.C., J.G.F., E.O., J.-P.C., and J.-C.B. recruited patients, analyzed data, and reviewed the manuscript; and M.-D.V.-P. performed histopathologic studies, analyzed data, and reviewed the manuscript. Conflict-of-interest disclosure: The authors declare no competing financial interests. Correspondence: Jean-Paul Fermand, De´partement d’immunologie clinique, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75010 Paris, France; e-mail: jp[email protected]

References 1. Parker F. Normocholesterolemic xanthomatosis. Arch Dermatol. 1986;122(11):1253-1257. 2. Cremer J. Retikulose mit Leberxanthomatose. Zentralbl Allg Pathol. 1937;68(8):289-298. 3. Misselwitz B, Goede JS, Pestalozzi BC, Schanz U, Seebach JD. Hyperlipidemic myeloma: review of 53 cases. Ann Hematol. 2010;89(6):569-577. 4. Mehregan DA, Winkelmann RK. Necrobiotic xanthogranuloma. Arch Dermatol. 1992;128(1):94100. 5. Kossard S, Winkelmann RK. Necrobiotic xanthogranuloma with paraproteinemia. J Am Acad Dermatol. 1980;3(3):257-270. 6. Feingold KR, Castro GR, Ishikawa Y, Fielding PE, Fielding CJ. Cutaneous xanthoma in association with paraproteinemia in the absence of hyperlipidemia. J Clin Invest. 1989;83(3):796-802. 7. Baudet MF, Dachet C, Beaumont JL. Interaction between fibroblasts, lipoproteins and three antilipoproteins IgA kappa. Clin Exp Immunol. 1980; 39(2):455-460. 8. Spicknall KE, Mehregan DA. Necrobiotic xanthogranuloma. Int J Dermatol. 2009;48(1):1-10. 9. Ginarte M, Peteiro C, Toribio J. Generalized plane xanthoma and idiopathic Bence-Jones proteinuria. Clin Exp Dermatol. 1997;22(4):192-194. 10. Escallier F. Vascularite hypocople´mente´miques, paraprote´ine´mie et xanthomes plans. Ann Dermatol Venereol. 1988;115:713-716. 11. Doutre MS, Conri C, Beylot C, Fleury B, Chapoulard H, Bioulac P. Normolipemic plane xanthomas and IgGk myeloma with antilipoprotein activity. Apropos of a case: review of the literature. Dermatologica. 1985;170(4):157164. 12. Loo DS, Kang S. Diffuse normolipidemic plane xanthomas with monoclonal gammopathy presenting as urticarial plaques. J Am Acad Dermatol. 1996;35(5):829-832. 13. Marcoval J, Moreno A, Bordas X, Gallardo F, Peyri J. Diffuse plane xanthoma: clinicopathologic study of 8 cases. J Am Acad Dermatol. 1998; 39(3):439-442. 14. Altman J, Winkelmann RK. Diffuse normolipemic plane xanthoma: generalized xanthelasma. Arch Dermatol. 1962;85:633-640. 15. Schifferli JA, Pascual M, Steiger G, et al. Fast liver catabolism of C1q in patients with paraproteinaemia and depletion of the classical pathway of complement. Clin Exp Immunol. 1987;69(1): 188-197. 16. Rotteleur G, Gaveau D, Guieu M, Dejobert Y, Krivosic I, Thomas P. Normolipemic diffuse xanthomatosis disclosing IgG kappa myeloma. Ann Dermatol Venereol. 1988;115(2):175-178. 17. Modiano P, Gillet-Terver MN, Reichert S, et al. Normolipemic plane xanthoma, monoclonal gammopathy, anti-lipoprotein activity, hypocomple-

mentemia. Ann Dermatol Venereol. 1995;122(8): 507-508. 18. Smith CH, Barker JN, Hay RJ. Diffuse plane xanthomatosis and acquired palmoplantar keratoderma in association with myeloma. Br J Dermatol. 1995;132(2):286-289. 19. Lonceint J, Jaussaud R, Vilque JP, Bernard P, Deville JF. Normolipemic plane xanthomas and non-Hodgkins malignant lymphomas. Ann Med Interne (Paris). 1999;150(2):162-163. 20. Stockman A, Delanghe J, Geerts ML, Naeyaert JM. Diffuse plane normolipaemic xanthomatosis in a patient with chronic lymphatic leukaemia and monoclonal gammopathy. Dermatology. 2002; 204(4):351-354. 21. Kourou K, Suga Y, Muramatsu S, Yaguchi H, Ogawa H. A case of diffuse plane normolipemic xanthomatosis associated with pancytopenia and monoclonal gammopathy. J Dermatol. 2006; 33(1):64-67. 22. Horne MK 3rd, Merryman P, Cullinane A, Remaley AT. In vitro characterization of a monoclonal IgG(kappa) from a patient with planar xanthomatosis. Eur J Haematol. 2008;80(6):495-502. 23. Polla L. Xanthomes plans et xanthogranulomes normolipe´miques, ulce`res a` types de pyoderma gangrenosum, mye´lome et hypocomple´mente´mie: a` propos de 2 observations. Dermatologica. 1984;169:287-290. 24. Casassus P. Planar xanthoma associated with a monoclonal immunoglobulin: improvement with a plasma exchange. Plasma Ther Transfus Technol. 1985;6:571. 25. Berard M, Antonucci M, Beaumont JL. Cytotoxic effect of serum on fibroblasts in one case of normolipidemic plane xanthoma and myeloma IgG lambda. Atherosclerosis. 1986;62(2):111-115. 26. Booken N, Goerdt S, Goebeler M. Diffuse plane normolipemic xanthomatosis associated with monoclonal gammopathy. Dermatology. 2009; 219(1):91-92. 27. Segner S, Theate I, Poire X, Tennstedt D, Marot L, Caers J. Diffuse xanthomatosis as a presenting feature of multiple myeloma. Eur J Haematol. 2010;84(5):460-461. 28. Goodenberger ME, Piette WW, Macfarlane DE, Argenyi ZB. Xanthoma disseminatum and Waldenstrom’s macroglobulinemia. J Am Acad Dermatol. 1990;23(5):1015-1018. 29. Malbran A, Parra LS, Casas JG, et al. Case report: diffuse plane xanthoma with low C4 and systemic inflammatory symptoms. Dermatol Online J. 2009;15(4):5. 30. Piccinno R, Menni S, Cavicchini S, Gianotti R. Normolipemic plane xanthomas and IgG-k multiple myeloma: description of a clinical case. G Ital Dermatol Venereol. 1990;125(10):449-451. 31. Juarez Y, Espana S, Lueiro M, Fernandez-Diaz ML, Bal F. Necrobiotic xanthogranuloma with scleroa-

trophic lichen associated with paraproteinemia. Actas Dermosifiliogr. 2006;97(9):603-608. 32. Wood AJ, Wagner MV, Abbott JJ, Gibson LE. Necrobiotic xanthogranuloma: a review of 17 cases with emphasis on clinical and pathologic correlation. Arch Dermatol. 2009;145(3): 279-284. 33. Bortolani A. Necrobiotic xanthogranuloma of the eyelids with paraproteinemia. Eur J Plast Surg. 1999;22:36-39. 34. Goede JS, Misselwitz B, Taverna C, et al. Necrobiotic xanthogranuloma successfully treated with autologous stem cell transplantation. Ann Hematol. 2007;86(4):303-306. 35. Ito Y, Nishimura K, Yamanaka K, et al. Necrobiotic xanthogranuloma with paraproteinemia; an atypical case. J Dtsch Dermatol Ges. 2008;6(1): 40-43. 36. Kraft J. Recalcitrant necrobiotic xanthogranuloma responding to Infliximab. J Am Acad Dermatol. 2005:52(3 suppl):p59. 37. Lazrak K, Machet MC, Forest JL, Machet L, Lorette G, Pasquiou C. Disseminated xanthosiderohistiocytosis with cardiac involvement and monoclonal gammapathy. Ann Dermatol Venereol. 1993;120(12):904-906. 38. Poiares-Baptista A, Goncalo S, Figueiredo A. Necrobiotic xanthogranuloma with paraproteinemia. Ann Dermatol Venereol. 1988;115(11):11471148. 39. Randell PL, Heenan PJ. Necrobiotic xanthogranuloma with paraproteinaemia. Australas J Dermatol. 1999;40(2):114-115. 40. Rayner SA, Duncombe AS, Keefe M, Theaker J, Manners RM. Necrobiotic xanthogranuloma occurring in an eyelid scar. Orbit. 2008;27(3):191194. 41. Saeki H, Tomita M, Kai H, et al. Necrobiotic xanthogranuloma with paraproteinemia successfully treated with melphalan, prednisolone and skin graft. J Dermatol. 2007;34(11):795-797. 42. Seve P, Zenone T, Durieu I, Moulin G, Levrat R. Necrobiotic xanthogranulomatosis: a cutaneous manifestation of a monoclonal IgM gammopathy. Rev Med Interne. 1998;19(5):338-340. 43. Spraul CW, Grossniklaus HE, Lang GK. Bilateral adult periocular xanthogranuloma. Klin Monatsbl Augenheilkd. 1997;211(5):342-344. 44. Venencie PY, Doukan S, Vieillefond A, et al. Necrobiotic xanthogranuloma with paraproteinemia. Ann Dermatol Venereol. 1992;119(11):825827. 45. Whyte A, Davies A, Jenkins C. Necrobiotic xanthogranuloma, a rare complication of a persistently high paraprotein. Br J Haematol. 2010; 150(1):1. 46. Khan IJ, Azam NA, Sullivan SC, Habboush HW,

From www.bloodjournal.org by guest on March 14, 2018. For personal use only. 3784

BLOOD, 6 OCTOBER 2011 䡠 VOLUME 118, NUMBER 14

SZALAT et al

Christian A. Necrobiotic xanthogranuloma successfully treated with a combination of dexamethasone and oral cyclophosphamide. Can J Ophthalmol. 2009;44(3):335-336. 47. Silapunt S, Chon SY. Generalized necrobiotic xanthogranuloma successfully treated with lenalidomide. J Drugs Dermatol. 2010;9(3):273-276. 48. Nozaki S, Ito Y, Nakagawa T, Yamashita S, Sasaki J, Matsuzawa Y. Autoimmune hyperlipidemia with inhibitory monoclonal antibodies against low density lipoprotein binding to fibroblasts in a case with multiple myeloma. Intern Med. 1997;36(12):920-925. 49. Levin WC, Aboumrad MH, Ritzmann SE, Brantly C. gamma-Type I myeloma and xanthomatosis. Arch Intern Med. 1964;114:688-693. 50. Yim H, Ahn HJ, Park C, Cheon JY. Xanthoma of the liver in a patient with multiple myeloma associated with hyperlipidemia: a case report. J Korean Med Sci. 1995;10(6):453-456. 51. Burnside NJ, Alberta L, Robinson-Bostom L, Bostom A. Type III hyperlipoproteinemia with xanthomas andmultiple myeloma. J Am Acad Dermatol. 2005;53(5 suppl 1):S281-S284. 52. Cortese C, Lewis B, Miller NE, et al. Myelomatosis with type III hyperlipoproteinemia: clinical and metabolic studies. N Engl J Med. 1982;307(2): 79-83. 53. Kodama H, Nakagawa S, Tanioku K. Plane xanthomatosis with antilipoprotein autoantibody. Arch Dermatol. 1972;105(5):722-727. 54. Hagiyama M, Arima T, Arata J, et al. Polymorphic type of xanthomatosis in association with IgA myeloma. J Dermatol. 1982;9(5):347-354. 55. Corsini A, Roma P, Sommariva D, Fumagalli R, Catapano AL. Autoantibodies to the low density lipoprotein receptor in a subject affected by severe hypercholesterolemia. J Clin Invest. 1986; 78(4):940-946. 56. Sharpe PC, Dawson JF, O’Kane MJ, Walsh MY, McMillan SA, Nicholls DP. Diffuse plane xanthomatosis associated with a monoclonal band displaying anti-smooth muscle antibody activity. Br J Dermatol. 1995;133(6):961-966. 57. Winkelmann RK, McEvoy MT. Diffuse-plane normolipaemic xanthoma with aortic-valve xanthoma. Clin Exp Dermatol. 1991;16(1):38-40. 58. Kovary PM, Cassuto JP, Dujardin P, et al. Hypocomplementemia of the first fractions of the classic pathway in normolipemic xanthoma planum with IgG1 monoclonal immunoglobulins (6 cases). Rev Med Interne. 1981;2(3):275-279. 59. Jones RR, Baughan AS, Cream JJ, Levantine A, Whicher JT. Complement abnormalities in diffuse

plane xanthomatosis with paraproteinaemia. Br J Dermatol. 1979;101(6):711-716. 60. Bazex A, Dupre A, Abravanel M. Normocholesteremic plane xanthomatous gamma plasmacytoma. Ann Dermatol Syphiligr (Paris). 1965;92: 139-150. 61. Beutler SM, Fretzin DF, Jao W, Desser R. Xanthomatosis resembling scleroderma in multiple myeloma. Arch Pathol Lab Med. 1978;102(11): 567-571. 62. Feiwel M. Xanthomatosis in cryoglobulinaemia and other paraproteinaemias with report of a case. Br J Dermatol. 1968;80(11):719-729. 63. Perrault M, Duperrat B, Dry J, Courmont J. Xanthoma planum with normal lipidemia and paraproteinemia. Ann Med Interne (Paris). 1971;122(6): 799-805. 64. Langlois S, Brochot P, Reguiai Z, et al. Necrobiotic xanthogranuloma with multiple myeloma: case report and pathogenic hypotheses. Joint Bone Spine. 2006;73(1):120-122. 65. Jeziorska M, Hassan A, Mackness MI, et al. Clinical, biochemical, and immunohistochemical features of necrobiotic xanthogranulomatosis. J Clin Pathol. 2003;56(1):64-68. 66. Macfarlane AW, Verbov JL. Necrobiotic xanthogranuloma with paraproteinaemia. Br J Dermatol. 1985;113(3):339-343. 67. Nestle FO, Hofbauer G, Burg G. Necrobiotic xanthogranuloma with monoclonal gammopathy of the IgG lambda type. Dermatology. 1999;198(4): 434-435. 68. Burdick AE, Sanchez J, Elgart GW. Necrobiotic xanthogranuloma associated with a benign monoclonal gammopathy. Cutis. 2003;72(1):4750. 69. Hunter L, Burry AF. Necrobiotic xanthogranuloma: a systemic disease with paraproteinemia. Pathology. 1985;17(3):533-536. 70. Ugurlu S, Bartley GB, Gibson LE. Necrobiotic xanthogranuloma: long-term outcome of ocular and systemic involvement. Am J Ophthalmol. 2000;129(5):651-657. 71. Yasukawa K, Kato N, Hamasaka A, Hata H. Necrobiotic xanthogranuloma: isolated skeletal muscle involvement and unusual changes. J Am Acad Dermatol. 2005;52(4):729-731. 72. Venencie PY, Puissant A, Verola O, et al. Necrobiotic xanthogranuloma with myeloma: a case report. Cancer. 1987;59(3):588-592. 73. Hauser C, Schifferli J, Saurat JH. Complement consumption in a patient with necrobiotic xanthogranuloma and paraproteinemia. J Am Acad Dermatol. 1991;24(5):908-911.

74. Wilhelmus KR, Yen MT, Rice L, Font RL. Necrobiotic xanthogranuloma with posterior scleritis. Arch Ophthalmol. 2006;124(5):748. 75. Valentine EA, Friedman HD, Zamkoff KW, Streeten BW. Necrobiotic xanthogranuloma with IgA multiple myeloma: a case report and literature review. Am J Hematol. 1990;35(4):283-285. 76. Oumeish OY, Oumeish I, Tarawneh M, Salman T, Sharaiha A. Necrobiotic xanthogranuloma associated with paraproteinemia and non-Hodgkin’s lymphoma developing into chronic lymphocytic leukemia: the first case reported in the literature and review of the literature. Int J Dermatol. 2006; 45(3):306-310. 77. Botto M, Kirschfink M, Macor P, Pickering MC, Wurzner R, Tedesco F. Complement in human diseases: lessons from complement deficiencies. Mol Immunol. 2009;46(14):2774-283. 78. Taylor JS, Lewis LA, Battle JD Jr, et al. Plane xanthoma and multiple myeloma with lipoproteinparaprotein complexing. Arch Dermatol. 1978; 114(3):425-431. 79. Meunier P, Gorin I, Delmer A, Escande JP. Diffuse normolipidemic plane xanthomatosis and monoclonal dysglobulinemia: a case with anti-lipoprotein activity of monoclonal immunoglobulin and hypocomplementemia. Ann Dermatol Venereol. 1996; 123(2):93-95. 80. Marten RH. Xanthomatosis and myelomatosis. Proc R Soc Med. 1962;55:318-319. 81. Maize JC, Ahmed AR, Provost TT. Xanthoma disseminatum and multiple myeloma. Arch Dermatol. 1974;110(5):758-761. 82. Rivat MH, Colomb D, Normand J, Cavailles M. Xanthomatosis and monoclonal myelomatous gammapathy. About a case also associated with systemic amyloidosis: review of 42 cases of literature (author’s transl). Ann Dermatol Venereol. 1979;106(10):755-766. 83. Timsit J, Lessana-Leibowitch M, Belkaid P, Najman A, Gorin NC, Duhamel G. Diffuse normolipemic xanthomatosis and IgG monoclonal dysglobulinemia. Ann Med Interne (Paris). 1982; 133(6):421-424. 84. Williford PM, White WL, Jorizzo JL, Greer K. The spectrum of normolipemic plane xanthoma. Am J Dermatopathol. 1993;15(6):572-575. 85. Buezo GF, Porras JI, Fraga J, Sanchez E, Aragues M, Dauden E. Coexistence of diffuse plane normolipaemic xanthoma and amyloidosis in a patient with monoclonal gammopathy. Br J Dermatol. 1996;135(3):460-462. 86. Hallermann C, Tittelbach J, Norgauer J, Ziemer M. Successful treatment of necrobiotic xanthogranuloma with intravenous immunoglobulin. Arch Dermatol. 2010;146(9):957-960.

From www.bloodjournal.org by guest on March 14, 2018. For personal use only.

2011 118: 3777-3784 doi:10.1182/blood-2011-05-356907 originally published online July 14, 2011

Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy Raphael Szalat, Bertrand Arnulf, Lionel Karlin, Michel Rybojad, Bouchra Asli, Marion Malphettes, Lionel Galicier, Marie-Dominique Vignon-Pennamen, Stéphanie Harel, Florence Cordoliani, Jean Gabriel Fuzibet, Eric Oksenhendler, Jean-Pierre Clauvel, Jean-Claude Brouet and Jean-Paul Fermand

Updated information and services can be found at: http://www.bloodjournal.org/content/118/14/3777.full.html Articles on similar topics can be found in the following Blood collections Clinical Trials and Observations (4718 articles) Free Research Articles (4927 articles) Lymphoid Neoplasia (2728 articles) Review Articles (747 articles) Information about reproducing this article in parts or in its entirety may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://www.bloodjournal.org/site/subscriptions/index.xhtml

Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved.